ADC TOXICITY ATLAS
AtlasPayloads and LinkersPayloadsTargetsMethods
← Atlas

Camidanlumab tesirine

Discontinued
ADCT-301; Cami; HuMax-TAC-ADC
Sponsor
ADC Therapeutics
Indication
CD25+ relapsed/refractory classic Hodgkin lymphoma (also Ph1 NHL & solid tumors)
Target family
Cytokine receptor
RP2D dose
0.045 mg/kg x2 then 0.03 mg/kg (45 ug/kg -> 30 ug/kg)
Q3W (21-day cycles); 45 ug/kg cycles 1-2 then 30 ug/kg for up to ~1 yearRP2D
01
Multi-organ toxicity

Fingerprint & organ drill-down

Also reported
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed
2 adverse-event terms

Ocular

Any-grade
0.9%
G3+
0%
RP2D
sagittal schematic · Unknown
↳

Tissues shaded by reported adverse-event rate.

Cornea
AE
-
Express.
-
Limbus
AE
-
Express.
-
Conjunctiva
AE
-
Express.
-
Lens
AE
-
Express.
-
Retina / RPE
AE
-
Express.
-
Dominant tissue
Periorbital/adnexa
Surface subtype
Unknown
Reversibility
Unknown
Reported ocular events
Blepharitis0.9%
Eye disorders, grade >=3 (any)-
G3+ 0%
02
Construct

Molecular anatomy

Antibody
IgG1
Human
Linker
Cleavable
Cleavable
2.3
DAR
Payload
SG3199 (PBD dimer)
DNA cross-linker
Linker structureC41H65N5O15
[H]OC([H])([H])c1c([H])c([H])c(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(=O)C([H])([H])C([H])([H])N2C(=O)C([H])=C([H])C2=O)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])c([H])c1[H]
Payload structureC33H36N4O6
CC1=CN2[C@@H](C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N=C[C@@H]6CC(=CN6C5=O)C)OC
03
Antibody

Antibody & Fc engineering

Antibody
Camidanlumab (HuMax-TAC)
Isotype
IgG1
Origin
Human
Fc modifications
None
Glycoengineering
Standard
Effector silencing
None (unmodified human IgG1 Fc; effector function retained)
FcγR binding
Retained
C1q binding
Retained
04
Linker & conjugation

Linker chemistry

Linker profile
Linker
VA dipeptide (tesirine) [Mal-PEG8-Val-Ala-PABC]
Class
Cleavable
Cleavage
Cleavable
Attachment
Cysteine (interchain)
Conjugation
Conventional interchain Cys (stochastic)
Symmetry
Symmetric
DAR (mean)
2.3
DAR homogeneity
Heterogeneous
Plasma t½
-
Cleavage trigger
Cathepsin B (Val-Ala)
Release control
Conditional
Hydrophilicity mask
Discrete-PEG-spacer
Formula
C41H65N5O15
Linker MW
867.991 Da
Linker TPSA
247.85 Ų
Linker xLogP
-0.2829
ADCdb linker
LIN0YRUBS
In-vitro stability
-
05
Payload

Payload & physicochemistry

Payload profile
Payload
SG3199 (PBD dimer)
Class
PBD dimer
Mechanism
DNA cross-linker
Released catabolite
SG3199 (pyrrolobenzodiazepine [PBD] dimer; DNA interstrand cross-linker)
Mechanistic subtype
DNA-crosslinker-PBD
Stereochem / salt
(11aS,11a'S)-configured PBD dimer (single defined stereoisomer); free base (no salt)
Bystander
Partial
PAMPA rank
-
MW
584.7 Da
XLogP3
2.8
logD₇.₄
2.5
TPSA
102 Ų
pKa
5 pKa
Charge pH 7.4
0
H-bond donors
0
H-bond acceptors
8
IC50 (HCEC)
-
Formula
C33H36N4O6
PubChem CID
90132565
ADCdb payload
PAY0LZRXU
Hydrophobicity · logD₇.₄
hydrophilic −2+2.5+4 lipophilic
Bioactivity note
ADCdb (DRG0FUFBP) reports in vitro GI50: 0.26 pM (EoL-1), 4.96 pM (SU-DHL-1), 17.07 pM (Karpas-299); in vivo up to 98.8% TGI at 0.6 mg/kg; clinical 48.6% CR in classical Hodgkin lymphoma at 45 ug/kg. Payload SG3199 is a highly potent PBD-dimer DNA interstrand crosslinker (the imi
06
Dosing & regimen

Dosing

RP2D dose
0.045 mg/kg x2 then 0.03 mg/kg (45 ug/kg -> 30 ug/kg)
Schedule
Q3W (21-day cycles); 45 ug/kg cycles 1-2 then 30 ug/kg for up to ~1 year
Route
IV
Fractionated
No
n at RP2D
117
Dose basis
TBW
Trial phase
Phase 2
Dose-OAE available
No
Tox summary basis
RP2D
07
Ocular & expression

Ocular profile & eye-tissue target expression

Target profile
OAE any-grade
0.9 %
OAE grade 3+
0 %
OAE data status
reported
Severity (weighted)
0.27
Keratopathy
-
Conjunctival
-
Dry eye
-
Blurred vision
-
Dominant tissue
Periorbital/adnexa
Surface subtype
Unknown
Grading scale
-
Reversibility
Unknown
Target expression in eye tissues (HCA detection · HPA bulk)
Cornea (central)
-
Cornea (limbal)
-
Conjunctiva
-
RPE
-
Retina (HPA)
-
Cross-trial comparability
Ascertainment: Symptom-driven reportingScale: UnknownDenominator: RP2D⚠ OAE rate not directly comparable across trials
08
Identity & registry

Identifiers, registry & notes

ADC id
camidanlumab-tesirine
Approval status
Discontinued
Approval year
-
UniProt
P01589
ADCdb ADC
DRG0FUFBP
ADCdb antibody
ANI0WWODM
ADCdb target
TAR0CYSHF
Primary source
Blood Adv 2025;9(23):6205 (PMID 40811783) — pivotal Ph2 cHL (ADCT-301-201 / NCT04052997, N=117); Hamadani Lancet Haematol 2021;8(6):e433 (PMID 34048682) — Ph1; ADCdb DRG0FUFBP
Aliases & development codes
ADCT-301; Cami; HuMax-TAC-ADC
Notes
Anti-CD25 (IL2RA) PBD-dimer ADC from ADC Therapeutics (HuMax-TAC human IgG1, stochastic interchain-Cys conjugation, DAR 2.3; ADCdb lists 2.25). Uses the SAME tesirine linker (Mal-PEG8-Val-Ala-PABC, ADCdb LIN0YRUBS) and SG3199 PBD-dimer payload as loncastuximab tesirine, so linker physchem and chemistry-input fields were carried from that verified row. MECHANISM is Treg-depleting / CD25-targeted. OCULAR (priority, why it qualifies): MINIMAL signal. In the pivotal Ph2 cHL study (ADCT-301-201 / NCT04052997, N=117 at RP2D 45 ug/kg Q3W x2 then 30 ug/kg), the ONLY eye-disorder AE was a single grade 1 blepharitis = 1/117 (0.9%); no corneal/conjunctival/dry-eye/blurred-vision/keratitis events and no grade >=3 ocular. Consistent with the PBD class (cf. loncastuximab/vadastuximab = ~0% OAE). ocular_surface_subtype set to 'Unknown' because blepharitis is an eyelid/adnexal event that does not map to the corneal/conjunctival/visual surface categories; the four specific surface-PT columns left blank (not separately reported) while oae_any=0.9 and oae_g3plus=0 are documented. DOMINANT toxicities are NOT ocular: skin/cutaneous 78.6% (G3+ 22.2%; maculopapular rash 32.5%, G3+ 6.8%) and immune-related GBS/polyradiculopathy 8/117 (6.8%; 5 grade >=3) — the latter is the AESI that led the FDA to require a much larger safety trial and the program to be paused/discontinued. NOTE: skin is not an organ_system in the toxicity_rows enum, so the dominant skin toxicity is recorded here rather than as a row. Other: fatigue 38.5%, hepatic enzyme rises (GGT 17.1%; 2 grade-3 DILI), cytopenias (lymphopenia G3+ 10.3% highest), nausea 27.4%, pneumonitis 3.4% + 1 grade-3 ILD, IRR 4.3% (all G1-2). 28.2% discontinued for TEAEs; ORR 70.1%, CR 33.3%. CTCAE version not stated in the Ph2 report (AEs coded with MedDRA v22.0), so ae_grading_scale left blank. Payload_physchem are standard shared SG3199 values. Clinical tier B (peer-reviewed primary); composition tier B (peer-reviewed + ADCdb); chemistry/payload tier C (derived from shared tesirine linker/SG3199 class).